Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Incyte
Company Monitoring Page for Incyte
latest headlines for company on cafepharma
Opportunities arise for once-spurned partners
EP Vantage
Fri, 05/13/22 - 10:34 am
Tags:
Pfizer
,
Biohaven
,
licensing
,
M&A
,
Aurinia
,
Bristol Myers Squibb
,
AbbVie
,
Alector
,
Arcus Biosciences
,
Biogen
,
Blueprint Medicines
,
CureVac
,
Gilead Sciences
,
GSK
,
Incyte
,
MorphoSys
,
Roche
,
Nestle
,
SAGE Therapeutics
,
Sarepta Therapeutics
,
Seres Therapeutics
,
Syndax
FDA approves new indication for drug to treat severe COVID-19
Beckers Hospital Review
Thu, 05/12/22 - 10:51 pm
Tags:
Eli Lilly
,
Incyte
,
baricitinib
,
FDA
,
olumiant
,
COVID-19
Incyte's Opzelura slapped with vitiligo delay amid topical JAK's eczema launch
Fierce Pharma
Mon, 03/14/22 - 11:37 pm
Tags:
Incyte
,
Opzelura
,
eczema
,
vitiligo
A new JAK inhibitor earns FDA nod in myelofibrosis, setting up a fight with Incyte, Bristol Myers
Endpoints
Tue, 03/1/22 - 10:35 am
Tags:
CTI BioPharma
,
JAK inhibitors
,
Vonjo
,
pacritinib
,
FDA
,
myelofibrosis
,
Incyte
,
Bristol Myers Squibb
Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data
Fierce Biotech
Wed, 02/2/22 - 10:59 am
Tags:
Novartis
,
Incyte
,
JAK inhibitors
,
Opzelua
,
eczema
,
atopic dermatitis
Eli Lilly, Incyte axe Olumiant in lupus amid eczema stalemate at FDA
Fierce Pharma
Fri, 01/28/22 - 11:47 am
Tags:
Eli Lilly
,
Incyte
,
olumiant
,
FDA
,
lupus
,
eczema
Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit
Fierce Biotech
Wed, 01/26/22 - 10:57 am
Tags:
Incyte
,
FDA
,
parsaclisib
FDA sets April date for verdict on Incyte’s vitiligo drug
Pharmaforum
Wed, 12/15/21 - 10:43 am
Tags:
Incyte
,
Opzelura
,
vitiligo
,
FDA
What Novartis could buy with its windfall
EP Vantage
Fri, 11/5/21 - 09:40 am
Tags:
Novartis
,
M&A
,
Roche
,
Sandoz
,
Aurinia Pharmaceuticals
,
Alnylam
,
Exelixis
,
Incyte
,
Eisai
,
Genmab
Incyte (INCY) Q3 Earnings and Revenues Beat Estimates
Yahoo/Zacks.com
Tue, 11/2/21 - 10:49 am
Tags:
Incyte
,
earnings
Lilly, Incyte: Olumiant Superior to Placebo in Scalp Hair Regrowth as Early as 24 Weeks
Marketwatch
Fri, 10/1/21 - 10:51 am
Tags:
Lilly
,
Incyte
,
clinial trials
,
olumiant
,
alopecia areata
Incyte and Syndax to jointly develop and commercialize axatilimab
Pharmaceutical Business Review
Tue, 09/28/21 - 12:01 pm
Tags:
Incyte
,
Syndax Pharma
,
axatilimab
,
graft vs host disease
Incyte on a Roll with Two FDA Wins in Two Days
BioSpace
Thu, 09/23/21 - 10:55 pm
Tags:
Incyte
,
FDA
,
Jakafi
,
graft vs host disease
,
ruxolitinib
,
atopic dermatitis
Incyte nabs approval of topical ruxolitinib in atopic dermatitis, but gets slapped with JAK warning
Endpoints
Wed, 09/22/21 - 11:17 am
Tags:
FDA
,
Incyte
,
atopic dermatitis
,
ruxolitinib
BioMarin stands tall with first approved drug for rare disease that causes dwarfism
MedCity News
Sat, 08/28/21 - 08:57 pm
Tags:
Biomarin
,
Europe
,
achondroplasia
,
dwarfism
,
Incyte
,
MorphoSys
Lilly has a bad hair day as Pfizer rival hits the mark in alopecia
Pharmaforum
Wed, 08/4/21 - 10:50 pm
Tags:
Eli Lilly
,
Incyte
,
Pfizer
,
alopecia areata
,
ritlecitinib
,
clinical trials
FDA unsurprisingly brings down the hammer on Incyte's PD-1 — drawing a line for future accelerated approvals
Endpoints
Mon, 07/26/21 - 09:36 am
Tags:
Incyte
,
retifanlimab
,
FDA
,
anal cancer
No fast way to eighth place for Incyte
EP Vantage
Fri, 06/25/21 - 10:58 am
Tags:
Macrogenics
,
Incyte
,
retifanlimab
,
monoclonal antibodies
,
FDA
FDA slams Incyte's PD-1 over single-arm study, low response and trial deaths
Endpoints
Wed, 06/23/21 - 11:06 am
Tags:
Incyte
,
FDA
,
clinical trials
,
retifanlimab
Incyte hits 2nd FDA delay in span of days, this time for atopic dermatitis hopeful ruxolitinib cream
Fierce Pharma
Sat, 06/12/21 - 10:23 pm
Tags:
Incyte
,
atopic dermatitis
,
ruxolitinib
,
FDA
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
cafepharma is a: rock, tree, site
*
Fill in the blank.